Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Costs of breast cancer treatment in the United Kingdom.

Dolan P, Torgerson DJ, Wolstenholme J.

Breast. 1999 Aug;8(4):205-7.

PMID:
14731442
[PubMed]
2.

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.

Wolowacz SE, Cameron DA, Tate HC, Bagust A.

J Clin Oncol. 2008 Feb 20;26(6):925-33. doi: 10.1200/JCO.2006.10.4190.

PMID:
18281666
[PubMed - indexed for MEDLINE]
Free Article
3.

The health care costs of diabetic nephropathy in the United States and the United Kingdom.

Gordois A, Scuffham P, Shearer A, Oglesby A.

J Diabetes Complications. 2004 Jan-Feb;18(1):18-26.

PMID:
15019595
[PubMed - indexed for MEDLINE]
4.

Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.

Counterweight Project Team.

J Health Serv Res Policy. 2008 Jul;13(3):158-66. doi: 10.1258/jhsrp.2008.007140.

PMID:
18573765
[PubMed - indexed for MEDLINE]
5.

The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK.

Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ; MRC Incontinence Team.

BJU Int. 2004 Jun;93(9):1246-52.

PMID:
15180616
[PubMed - indexed for MEDLINE]
6.

Estimates of the lifetime direct costs of treatment for metastatic breast cancer.

Berkowitz N, Gupta S, Silberman G.

Value Health. 2000 Jan-Feb;3(1):23-30.

PMID:
16464178
[PubMed]
7.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

PMID:
16959170
[PubMed - indexed for MEDLINE]
Free Article
8.

The cost-effectiveness of screening for oral cancer in primary care.

Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M, Augustovski F.

Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv. Review.

PMID:
16707071
[PubMed - indexed for MEDLINE]
Free Article
9.

Cost of cardiovascular diseases in the United Kingdom.

Luengo-Fernández R, Leal J, Gray A, Petersen S, Rayner M.

Heart. 2006 Oct;92(10):1384-9. Epub 2006 May 15.

PMID:
16702172
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.

Maslove L, Gower N, Spiro S, Rudd R, Stephens R, West P.

Thorax. 2005 Jul;60(7):564-9.

PMID:
15994264
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J.

Pharmacoeconomics. 2008;26(7):617-27.

PMID:
18563952
[PubMed - indexed for MEDLINE]
12.
13.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

PMID:
17245000
[PubMed - indexed for MEDLINE]
Free Article
14.

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.

Clin Ther. 2005 Aug;27(8):1295-310.

PMID:
16199254
[PubMed - indexed for MEDLINE]
15.

The economic consequences of prostate and bladder cancer in the UK.

Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA.

BJU Int. 2005 Jan;95(1):59-63.

PMID:
15638895
[PubMed - indexed for MEDLINE]
16.

Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.

Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, Chakravathy U, Carpenter J, Reeves BC; Verteporfin Photodynamic Therapy Cohort Study Group.

Ophthalmology. 2009 Dec;116(12):2471-77.e1-2. doi: 10.1016/j.ophtha.2009.10.023.

PMID:
19948278
[PubMed - indexed for MEDLINE]
17.

Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.

Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G.

J Support Oncol. 2006 Jul-Aug;4(7):341-7.

PMID:
16892696
[PubMed - indexed for MEDLINE]
18.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
[PubMed - indexed for MEDLINE]
19.

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.

Wade AG, Toumi I, Hemels ME.

Clin Ther. 2005 Apr;27(4):486-96.

PMID:
15922821
[PubMed - indexed for MEDLINE]
20.

Cost implications of sexual dysfunction: the female picture.

Goldmeier D, Malik F, Phillips R, Green J.

Int J Impot Res. 2004 Apr;16(2):130-4.

PMID:
14961049
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk